Zacks Investment Research upgraded shares of CURIS INC (CRIS) from NEUTRAL to OUTPERFORM on November 12, 2012, with a target price of $3.50.
Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CURIS INC (CRIS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment